Desmoplastic Small Round Cell Tumor Overview

Save information for later
Sign Up

Learn About Desmoplastic Small Round Cell Tumor

What is the definition of Desmoplastic Small Round Cell Tumor?
Desmoplastic small round cell tumor (DSRCT) is a rare type of soft tissue cancer (sarcoma) that usually begins in the abdomen. It primarily affects children and young adults and is more common in males. It is formed by small, round cancer cells surrounded by scar-like tissue and is often found in the tissue (peritoneum) that lines the inside of the abdomen and pelvis. The tumor cells have a characteristic genetic change involving a translocation between chromosomes 11 and 22, which is important in differentiating from other similar tumors. The genetic change involved in DSRCT is acquired throughout a person's lifetime and is not inherited. Symptoms may include abdominal pain and a feeling of fullness, abdominal mass, and symptoms of gastrointestinal obstruction, such as constipation.
What are the alternative names for Desmoplastic Small Round Cell Tumor?
  • Desmoplastic small round cell tumor
  • DSRCT
  • Desmoplastic small round-cell tumor
Who are the top Desmoplastic Small Round Cell Tumor Local Doctors?
Mark A. Dickson
Elite in Desmoplastic Small Round Cell Tumor
Dr. Mark A. Dickson
Hematology Oncology | Hematology | Oncology
Elite in Desmoplastic Small Round Cell Tumor
Dr. Mark A. Dickson
Hematology Oncology | Hematology | Oncology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Dickson is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Dickson is rated as an Elite provider by MediFind in the treatment of Desmoplastic Small Round Cell Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Undifferentiated Pleomorphic Sarcoma, Gastrointestinal Stromal Tumor, and Endoscopy.

Elite in Desmoplastic Small Round Cell Tumor
Dr. William D. Tap
Hematology Oncology | Hematology | Oncology
Elite in Desmoplastic Small Round Cell Tumor
Dr. William D. Tap
Hematology Oncology | Hematology | Oncology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

William Tap is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Tap is rated as an Elite provider by MediFind in the treatment of Desmoplastic Small Round Cell Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Angiosarcoma, Tissue Biopsy, and Liver Embolization.

 
 
 
 
Learn about our expert tiers
Learn More
Peter Anderson
Elite in Desmoplastic Small Round Cell Tumor
Dr. Peter Anderson
Pediatrics
Elite in Desmoplastic Small Round Cell Tumor
Dr. Peter Anderson
Pediatrics

Cleveland Clinic Children's Outpatient Center

8950 Euclid Avenue, 
Cleveland, OH 
216-444-8950
Experience:
50+ years
Languages Spoken:
English
See accepted insurances

Peter Anderson is a Pediatrics provider in Cleveland, Ohio. Dr. Anderson has been practicing medicine for over 50 years and is rated as an Elite provider by MediFind in the treatment of Desmoplastic Small Round Cell Tumor. His top areas of expertise are Osteosarcoma, Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, and Adult Soft Tissue Sarcoma.

View All Doctors
What are the latest Desmoplastic Small Round Cell Tumor Clinical Trials?
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Who is this study for: Patients with Solid Tumors
Enrollment Status: Recruiting
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drugs: Fludarabine, Cyclophosphamide, MESNA, B7-H3 CAR T cells
Study Phase: Phase 1

Summary: 3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old, with relapsed/refractory B7-H3+ solid tumors. This study will evaluate the safety and maximum tolerated dose of B7-H3-CAR T cells.The purpose of this study is to find the ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Allogeneic Stem Cell Transplantation Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion With Zoledronic Acid in Combination to Treat Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory Solid Tumors
Allogeneic Stem Cell Transplantation Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion With Zoledronic Acid in Combination to Treat Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory Solid Tumors
Enrollment Status: Recruiting
Publish Date: September 23, 2025
Intervention Type: Drug, Device
Study Phase: Phase 1/Phase 2

Summary: Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for hematologic malignancies and non-malignant diseases additionally increasing the donor pool as to allow for haploidentical transplant to safely occur. While solid tumors can be h...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center